Tuesday, 23 Jan 2018

You are here

Statins Improve Survival in Ankylosing Spondylitis

Systemic inflammation (from underling inflammatory polyarthritis) clearly accelerates atherosclerosis with a resultant increase risk of cardiovascular disease.

A recent population-based cohort study published by Dr. Exarchou et al showed that patients with ankylosing spondylitis (AS) are at 60% increased risk of premature mortality with CV events being more common in AS than in the general population (1). At the same time there is little known about how CV risk factor modification modalities may affect this outcome. In multiple RA studies it has been shown that statin initiation can decrease CV mortality risk by up to 20%.

In a recent study, conducted by a researchers from UK , the goal was to investigate similar relationships between statin initiation and the risk of all-cause mortality in patients with AS in a general population context.

This population-based cohort study compared adult AS patients who carried a diagnosis of AS for at least a year between 2000 and 2014 to the general population. 

1430 AS patients who started a statin were randomly matched 1:1 and compared to statin non-initiators. It was observed that patients in the statin group had higher prevalence of CV disease, more CV risk factors and higher use of CV medications (confounding by indication).

After initial characteristic groups were balanced in statistical analysis, mortality rates in statin initiation and statin non-initiation groups were 16.5 and 23.8 per 1000 PYs, respectively, and the HR for mortality associated with statin initiation was 0.63 (95% CI 0.46 to 0.85). The corresponding absolute mortality rate difference was 7.3 deaths per 1000 PYs (95% CI 2.1 to 12.5).

Statin initiation was associated with a 37% reduction in all-cause mortality. This association was independent of age, sex, BMI socioeconomic status, relevant comorbidities, cardiovascular medication use, total cholesterol levels and healthcare utilization.

Interestingly, the magnitude of this association was much higher in AS as compared to similar RA studies. Further studies would be required to define the role of statin use in AS care, which could potentially lead to incorporation of statin therapy into guidelines for the management of cardiovascular risk in AS.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Apremilast’s Rapid Onset in Psoriatic Arthritis

Monotherapy with apremilast (Otezla) among patients with psoriatic arthritis who were biologic-naive was significantly more effective than placebo as early as week 2 in a phase IIIb study. 

Salt Drives Gut-Brain Connection via IL-17

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease

Patients with ankylosing spondylitis (AS) have shown rapid and sustained responses to secukinumab (Cosentyx) in a third phase III trial that includes a higher dose of this anti-interleukin-17A monoclonal antibody, researchers reported.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

Cardiac Disturbances Increased in Spondyloarthritis

A prospective Swedish study between 2001–2009 found a higher risk of aortic regurgitation, pacemaker, AV block and atrial fibrillation in SpA, AS, uSpA and PsA patients.